Evolus, Inc. announced its preliminary unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The company reported a preliminary unaudited net revenue of $79.0 million for the fourth quarter of 2024, representing a 30% growth over the prior year. For the full-year 2024, the preliminary unaudited net revenue was $266.3 million, indicating a 32% growth over the prior year and at the top of the company’s guidance.
The company expects U.S. Food and Drug Administration (FDA) approval within 90 days for evolysse™ form and evolysse™ smooth injectable hyaluronic acid (HA) gels, with a U.S. launch planned for Q2 2025, a full quarter ahead of the prior timeline.
Looking ahead, Evolus provided its 2025 net revenue guidance of $345 million to $355 million, representing 30% to 33% growth from preliminary 2024 results. The company anticipates evolysse™ and estyme® injectable HA gels to contribute 8-10% of total revenue for the full-year 2025.
In terms of non-GAAP operating expenses, Evolus expects them to be $230 million to $240 million for 2025, with expected profitability for the full-year 2025. The company aims to achieve positive non-GAAP operating income on a consolidated basis for the full-year 2025, with non-GAAP operating income concentrated in Q4 2025.
Evolus reported that total net revenues for the fourth quarter of 2024 were $79.0 million, a 30% increase over the fourth quarter of 2023, driven primarily by higher volumes and market share gains. The total net revenues for full-year 2024 were $266.3 million, a 32% increase over full-year net revenues in 2023, exceeding 30% growth for the fifth consecutive year, and at the top of the company’s guidance of $260 million to $266 million.
Furthermore, the company highlighted that accounts purchasing jeuveau® increased by approximately 830 in the fourth quarter, which is approximately 20% above the year-to-date quarterly average in their seasonally highest performance quarter. Additionally, enrollment in the Evolus rewards consumer loyalty program grew over 40% in 2024 to end the year at approximately 1.1 million consumers.
As of December 31, 2024, Evolus had cash and cash equivalents of $87.0 million compared to $85.0 million on September 30, 2024, reflecting strong sales growth, cash collections, and prudent expense management.
Evolus, Inc. is a global performance beauty company with a focus on building an aesthetic portfolio. Its mission is to become a global, multi-product aesthetics company based on its flagship product, jeuveau® (prabotulinumtoxina-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using hi-pure™ technology.
The company is expanding its product portfolio and has entered into a definitive agreement to be the exclusive U.S. distributor of evolysse™ and the exclusive distributor in Europe of estyme®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans for a launch starting in 2025. The market has reacted to these announcements by moving the company's shares 28.9% to a price of $13.54. For more information, read the company's full 8-K submission here.
